Categories
Jump to navigation
Jump to search
The following categories exist on the wiki, and may or may not be unused. Also see wanted categories.
(first | last) View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)- Bladder cancer medications (investigational) (0 members)
- Bladder cancer regimens (3 members)
- Blastic plasmacytoid dendritic cell neoplasm medications (1 member)
- Blastic plasmacytoid dendritic cell neoplasm regimens (1 member)
- Bleeding disorders (5 members)
- Bone marrow failure syndromes (6 members)
- Bone protective medications (2 members)
- Bone sarcoma medications (3 members)
- Bone sarcoma regimens (4 members)
- Bone sarcomas (11 members)
- Bowel management (2 members)
- Breast cancer medications (70 members)
- Breast cancer medications (historic) (21 members)
- Breast cancer medications (investigational) (5 members)
- Breast cancer pages (2 members)
- Breast cancer regimens (15 members)
- Bristol-Myers Squibb product (2 members)
- Burkitt lymphoma medications (17 members)
- Burkitt lymphoma regimens (1 member)
- CDK4 inhibitors (4 members)
- CDK6 inhibitors (4 members)
- CDK inhibitors (4 members)
- CFDA approved drugs (0 members)
- CK1 epsilon inhibitors (1 member)
- CK1 inhibitors (1 member)
- CNS cancers (8 members)
- CNS carcinoma medications (0 members)
- CNS carcinoma regimens (1 member)
- CNS hemangioblastoma medications (1 member)
- CNS leukemia medications (5 members)
- CNS leukemia regimens (1 member)
- CNS lymphoma medications (27 members)
- CNS lymphoma regimens (2 members)
- CNS melanoma regimens (1 member)
- COX-1 inhibitors (4 members)
- COX-2 inhibitors (2 members)
- CSF1R inhibitors (5 members)
- CXCR4 inhibitors (2 members)
- CYP17 inhibitors (5 members)
- Calcineurin inhibitors (2 members)
- Cannabinoid (2 members)
- Carbonic anhydrase inhibitors (1 member)
- Carcinoma of unknown primary medications (16 members)
- Carcinoma of unknown primary regimens (1 member)
- Castleman disease medications (12 members)
- Castleman disease regimens (2 members)
- Cellular therapy (13 members)
- Cellular therapy regimens (1 member)
- Cephalosporin (2 members)
- Cephalotaxine (1 member)
- Cereblon E3 ubiquitin ligase modulators (1 member)
- Cervical cancer medications (26 members)
- Cervical cancer regimens (3 members)
- Chelators (5 members)
- Chemotherapy protective agents (12 members)
- Chimeric antigen receptor T-cells (6 members)
- Cholangiocarcinoma medications (27 members)
- Cholangiocarcinoma regimens (2 members)
- Chronic lymphocytic leukemia medications (34 members)
- Chronic lymphocytic leukemia medications (historic) (5 members)
- Chronic lymphocytic leukemia medications (investigational) (4 members)
- Chronic lymphocytic leukemia regimens (3 members)
- Chronic myelogenous leukemia medications (historic) (0 members)
- Chronic myelogenous leukemia medications (investigational) (0 members)
- Chronic myelogenous leukemia regimens (0 members)
- Chronic myeloid leukemia medications (20 members)
- Chronic myeloid leukemia medications (historic) (3 members)
- Chronic myeloid leukemia medications (investigational) (0 members)
- Chronic myeloid leukemia regimens (3 members)
- Chronic myelomonocytic leukemia medications (5 members)
- Chronic myelomonocytic leukemia regimens (1 member)
- Classical Hodgkin lymphoma medications (44 members)
- Classical Hodgkin lymphoma medications (historic) (8 members)
- Classical Hodgkin lymphoma medications (investigational) (1 member)
- Classical Hodgkin lymphoma regimens (5 members)
- Classical hematologic conditions (7 members)
- Classical hematology medications (23 members)
- Classical hematology regimens (18 members)
- Clear cell renal cell carcinoma medications (10 members)
- Clear cell renal cell carcinoma regimens (2 members)
- Clinical pharmacology (16 members)
- Clusterin inhibitor (1 member)
- Coagulation factors (11 members)
- Coagulopathy medications (1 member)
- Coagulopathy regimens (4 members)
- Cold agglutinin disease medications (11 members)
- Cold agglutinin disease medications (investigational) (0 members)
- Cold agglutinin disease regimens (1 member)
- Colon cancer medications (9 members)
- Colon cancer medications (historic) (6 members)
- Colon cancer medications (investigational) (1 member)
- Colon cancer regimens (8 members)
- Colorectal cancer medications (46 members)
- Colorectal cancer medications (historic) (1 member)
- Colorectal cancer medications (investigational) (0 members)
- Colorectal cancer regimens (6 members)
- Colorectal cancers (10 members)
- Combination drugs (8 members)
- Complement factor D inhibitors (1 member)
- Complement pathway inhibitors (2 members)
- Complementopathies (4 members)
- Complementopathy medications (3 members)
- Complementopathy regimens (3 members)
- Condition (3 members)
- Congenital thrombotic thrombocytopenic purpura medications (1 member)
- Craniopharyngioma medications (2 members)
- Craniopharyngioma regimens (1 member)
- Cross-disciplinary conditions (4 members)
- Cutaneous T-cell lymphoma medications (15 members)
- Cutaneous T-cell lymphoma medications (investigational) (1 member)
- Cutaneous T-cell lymphoma regimens (2 members)
- Cutaneous basal cell carcinoma medications (7 members)
- Cutaneous basal cell carcinoma regimens (1 member)
- Cutaneous lymphomas (2 members)
- Cutaneous squamous cell carcinoma medications (8 members)
- Cutaneous squamous cell carcinoma regimens (2 members)
- Cytokines (2 members)
- Cytopenias (8 members)
- Cytotoxic T-cells (1 member)
- Cytotoxic chemotherapeutic (17 members)
- DDR inhibitors (1 member)
- DNA methyltransferase inhibitors (5 members)
- Dendritic cell vaccines (1 member)
- Deoxycytidine analogs (3 members)
- Deoxycytidine analogues (0 members)
- Dermatofibrosarcoma protuberans medications (1 member)
- Dermatofibrosarcoma protuberans regimens (1 member)
- Desmoid tumor medications (8 members)
- Desmoid tumor medications (investigational) (0 members)
- Desmoid tumor regimens (2 members)
- Devices (1 member)
- Diffuse large B-cell lymphoma medications (62 members)
- Diffuse large B-cell lymphoma medications (historic) (8 members)
- Diffuse large B-cell lymphoma medications (investigational) (3 members)
- Diffuse large B-cell lymphoma regimens (3 members)
- Direct oral anticoagulants (5 members)
- Direct thrombin inhibitors (4 members)
- Discontinued drugs (37 members)
- Disease-specific pages (281 members)
- Diuretics (1 member)
- Dopamine receptor antagonist (6 members)
- Drug manufacturers (10 members)
- Drugs (781 members)
- Drugs by local effect (4 members)
- Drugs by vehicle (3 members)
- EGFR inhibitors (18 members)
- EGFR medications (0 members)
- EGFR regimens (0 members)
- EMA approved drugs (60 members)
- EMA approved in 1952 (1 member)
- EMA approved in 1953 (1 member)
- EMA approved in 1955 (1 member)
- EMA approved in 1956 (2 members)
- EMA approved in 1957 (1 member)
- EMA approved in 1958 (2 members)
- EMA approved in 1959 (3 members)
- EMA approved in 1962 (2 members)
- EMA approved in 1963 (2 members)
- EMA approved in 1966 (4 members)
- EMA approved in 1967 (1 member)
- EMA approved in 1970 (1 member)
- EMA approved in 1971 (2 members)
- EMA approved in 1974 (2 members)
- EMA approved in 1976 (3 members)
- EMA approved in 1977 (1 member)
- EMA approved in 1978 (2 members)
- EMA approved in 1979 (2 members)
- EMA approved in 1980 (2 members)
- EMA approved in 1981 (2 members)
- EMA approved in 1982 (5 members)
- EMA approved in 1984 (3 members)
- EMA approved in 1986 (3 members)
- EMA approved in 1987 (1 member)
- EMA approved in 1988 (1 member)
- EMA approved in 1989 (4 members)
- EMA approved in 1991 (1 member)
- EMA approved in 1992 (2 members)
- EMA approved in 1993 (2 members)
- EMA approved in 1994 (2 members)
- EMA approved in 1995 (9 members)
- EMA approved in 1996 (8 members)
- EMA approved in 1997 (1 member)
- EMA approved in 1998 (5 members)
- EMA approved in 1999 (1 member)
- EMA approved in 2000 (2 members)
- EMA approved in 2001 (9 members)
- EMA approved in 2002 (3 members)
- EMA approved in 2003 (2 members)
- EMA approved in 2004 (6 members)
- EMA approved in 2005 (3 members)
- EMA approved in 2006 (4 members)
- EMA approved in 2007 (7 members)
- EMA approved in 2008 (8 members)
- EMA approved in 2009 (9 members)
- EMA approved in 2010 (7 members)
- EMA approved in 2011 (6 members)
- EMA approved in 2012 (8 members)
- EMA approved in 2013 (15 members)
- EMA approved in 2014 (8 members)
- EMA approved in 2015 (12 members)
- EMA approved in 2016 (11 members)
- EMA approved in 2017 (14 members)
- EMA approved in 2018 (12 members)
- EMA approved in 2019 (13 members)
- EMA approved in 2020 (15 members)
- EMA approved in 2021 (18 members)
- EMA approved in 2022 (18 members)
- EMA approved in 2023 (12 members)
- EMA approved in 2024 (1 member)
- EMA withdrawn in 2012 (1 member)
- EMA withdrawn in 2013 (1 member)
- EMA withdrawn in 2015 (1 member)
- EMA withdrawn in 2017 (2 members)
- EMA withdrawn in 2018 (1 member)
- EMA withdrawn in 2019 (2 members)
- EMA withdrawn in 2020 (1 member)
- EMA withdrawn in 2021 (2 members)
- ERBB2 (HER2) medications (0 members)
- ERBB2 (HER2) regimens (0 members)
- ERBB2 inhibitors (6 members)
- ERBB3 (HER3) medications (0 members)
- ERBB3 (HER3) regimens (0 members)
- ERBB3 inhibitors (1 member)
- ERBB4 inhibitors (3 members)
- EZH1 inhibitors (1 member)
- EZH2 inhibitors (2 members)
- Emesis prevention (34 members)
- Endocrine ablation radiation (1 member)
- Endocrine ablation surgery (3 members)
- Endocrine cancers (15 members)
- Endocrine oncology medications (4 members)
- Endocrine oncology regimens (1 member)
- Endocrine therapeutic (18 members)
- Endometrial cancer medications (25 members)
- Endometrial cancer regimens (2 members)
- Enediyne antibiotic (2 members)
- Enzyme activator (1 member)
- Enzyme inhibitors (14 members)
- Enzymes (1 member)
- Epithelioid sarcoma medications (1 member)
- Epithelioid sarcoma regimens (1 member)
- Epothilones (1 member)
- Erdheim-Chester disease medications (4 members)
- Erdheim-Chester disease regimens (1 member)
- Erythrocyte growth factors (5 members)
- Esophageal adenocarcinoma medications (18 members)
- Esophageal cancer medications (41 members)
- Esophageal cancer medications (investigational) (0 members)
- Esophageal cancer regimens (6 members)
- Esophageal cancers (1 member)